Prima BioMed PE Ratio 2010-2021 | IMMP

Current and historical p/e ratio for Prima BioMed (IMMP) from 2010 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Prima BioMed PE ratio as of August 09, 2022 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Prima BioMed PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2022-08-09 2.23 inf
2021-12-31 3.28 0 0.00
2017-03-31 2.44 0 0.00
2016-12-31 2.34 0 0.00
2016-06-30 3.23 0 0.00
2015-06-30 4.83 0 0.00
2014-12-31 2.23 0 0.00
2014-06-30 3.87 0 0.00
2013-12-31 3.67 0 0.00
2013-06-30 6.98 0 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.196B $0.003B
Immutep Limited is a biotechnology company. It engaged in developing novel immunotherapy treatments for cancer and autoimmune disease. The company's product pipeline consists of eftilagimod alpha, IMP731, IMP701 and IMP761 which are in clinical stage. It operates primarily in Europe, Australia and the U.S. Immutep Limited, formerly known as Prima BioMed Ltd, is headquartered in Sydney, Australia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $157.582B 9.56
GSK (GSK) United Kingdom $81.978B 9.84
Bio-Rad Laboratories (BIO.B) United States $16.008B 35.37
QIAGEN (QGEN) Netherlands $11.229B 18.80
Biohaven Pharmaceutical Holding (BHVN) United States $10.520B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.756B 0.00
Arcus Biosciences (RCUS) United States $1.974B 38.52
Emergent Biosolutions (EBS) United States $1.523B 8.83
Myovant Sciences (MYOV) United Kingdom $1.503B 0.00
Zymeworks (ZYME) Canada $0.405B 0.00
Enzo Biochem (ENZ) United States $0.125B 0.00
SQZ Biotechnologies (SQZ) United States $0.098B 0.00
Gelesis Holdings (GLS) United States $0.098B 0.00
Ambrx Biopharma (AMAM) United States $0.092B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00